Abstracts Archive - Page 1325 of 2425 - ACR Meeting Abstracts

Abstract Number: 1792 • 2017 ACR/ARHP Annual Meeting
Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?
Xiaofei Xu¹, Nadine Davelaar², Anne-Marie Otten-Mus³, Patrick Asmawidjaja², J.M.W. Hazes⁴, Dominique Baeten⁵, Marijn Vis⁶, Radjesh Bisoendial¹ and Erik Lubberts², ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: TNF and IL-17A are proinflammatory cytokines critically involved in the pathogenesis of psoriatic arthritis (PsA). Currently, targeting TNF is the first choice of a…
Abstract Number: 1793 • 2017 ACR/ARHP Annual Meeting
Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis
Debbie M. Roeleveld¹, Loreto Parga Vidal², Monique M. Helsen², Birgitte Walgreen³, Bianka Marklein⁴, Karl Skriner⁵, Martin Hegen⁶, Peter L. van Lent², Fons A.J. van de Loo², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands, ⁴Humboldt University and Free University, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 1794 • 2017 ACR/ARHP Annual Meeting
Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice
Debbie M. Roeleveld¹, Monique M. Helsen², Birgitte Walgreen³, Elly Vitters², Fons A.J. van de Loo², Peter L. van Lent², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 1795 • 2017 ACR/ARHP Annual Meeting
IL-7 in Primary Sjogren Syndrome (pSS) Is Secreted By Salivary Gland Epithelial Cells after IFN Stimulation and Is Associated with B-Cell Activation
Alexandre Virone¹, Juliette Pascaud², Elodie Rivière¹, Jacques-Eric Gottenberg³, Véronique Le Guern⁴, Xavier Mariette¹ and Gaetane Nocturne⁵, ¹Université Paris Sud, Paris, France, ²U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ³CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France
Background/Purpose : pSS is characterized by a strong IFN signature, ectopic germinal centers formation and a chronic blood lymphopenia. IL-7 plays a central part in…
Abstract Number: 1796 • 2017 ACR/ARHP Annual Meeting
Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of Phase II of a Cluster Randomized Controlled Trial
Daniel H. Solomon¹, Liana Fraenkel², Zhi Yu³, Bing Lu⁴, Asaf Bitton⁵, Agnes Zak⁶, Cassandra Corrigan⁷, Jen Agosti⁸, Leslie R Harrold⁹, Josef S. Smolen¹⁰, Jeffrey N. Katz¹¹ and Elena Losina¹², ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ³Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Medicine, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸JRA Consulting, Andover, MA, ⁹University of Massachusetts Medical School, Worcester, MA, ¹⁰Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ¹¹Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ¹²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but its uptake in routine rheumatologic care in…
Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Malithi Jayasundara¹, Ryan Jessee², Jason Weiner³, Tayseer Haroun⁴, Stephanie Giattino⁵, Atul Kapila⁴, Jenelle Hall⁴, Lisa Carnago⁴ and Lisa Criscione-Schreiber⁶, ¹Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Rheumatology, Duke University Medical Center, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…
Abstract Number: 1798 • 2017 ACR/ARHP Annual Meeting
Effective Implementation and Evaluation of Quality Improvement Initiatives in a Safety Net Hospital Rheumatology Clinic
Alfredo Aguirre¹, Laura Trupin², Mary Margaretten³, Sarah Goglin⁴ and Jinoos Yazdany², ¹Internal Medicine, University of California, San Francisco, SAN FRANCISCO, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Vulnerable populations with autoimmune rheumatic diseases are at higher risk for disparities in care. To address these health inequalities we developed and evaluated 2…
Abstract Number: 1799 • 2017 ACR/ARHP Annual Meeting
Time to First Appointment Among Young Adults Transitioning from Pediatric to Adult Rheumatologic Care in a Safety Net Population
Nicole Bitencourt¹, Una E. Makris^1,2, Tracey Wright^3,4 and E. Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²Department of Medicine, VA North Texas Health Care System, Dallas, TX, ³Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ⁴Texas Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: For young adults with a chronic rheumatic illness transitioning from pediatric to adult care, the transfer to new system can be daunting; these challenges…
Abstract Number: 1800 • 2017 ACR/ARHP Annual Meeting
Do Patient Reported Outcome Measurement Information System (PROMIS) Computer Adaptive Tests Correlate with Disease Activity in Juvenile Idiopathic Arthritis?
Rebecca Trachtman¹, Elizabeth T. Murray², Jackie Szymonifka³, Alexa Adams⁴, Nancy Pan⁴, Sarah Taber⁴, Thomas J. A. Lehman⁴, Karen Onel⁴ and Lisa A. Mandl⁵, ¹Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁵Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: The importance of patient-reported outcomes is increasingly recognized both in clinical care and in research. PROMIS is an NIH-supported collection of patient-reported outcome measures,…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 1802 • 2017 ACR/ARHP Annual Meeting
Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Francis Guillemin¹, Marie-Line Erpelding², Annette de Thurah^3,4,5,6, Elena Myasoedova⁷, Emilce E Schneeberger⁸, Cynthia S. Crowson⁹, Thomas Maribo¹⁰, Gustavo Citera¹¹, Eric L. Matteson¹² and Bruno Fautrel¹³, ¹University of Lorraine, Nancy, France, Nancy, France, ²CIC 1433 Clinical Epidemiology, Inserm, Nancy, France, ³Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁰DEFACTUM, Central Region Denmark, Aarhus, Denmark, ¹¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Flare-RA questionnaire was developed and validated in French (1) for assessing the occurrence of a flare of rheumatoid arthritis (RA) during a 3-month…
Abstract Number: 1803 • 2017 ACR/ARHP Annual Meeting
A Cluster Analysis Approach to Patient-Physician Discordance in Rheumatoid Arthritis Activity Evaluations Optimally Differentiates and Predicts Clinical, Functional and Quality of Life Outcomes
George Karpouzas¹ and Sarah Ormseth², ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Patients and physicians commonly differ in their evaluations of rheumatoid arthritis (RA) activity. However, clinically meaningful thresholds for such discordance or validation of their…
Abstract Number: 1804 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes and Damage Predict Mortality in Lupus
Desiree R Azizoddin¹, Meenakshi Jolly², Patricia P. Katz³ and Edward H. Yelin⁴, ¹Department of Psychology, Loma Linda University, Loma Linda, CA, ²Rush, Chicago, IL, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Physician-assessed disease activity and damage predict mortality in systemic lupus erythematosus (SLE). Patient-reported outcomes (PROs) are known predictors of mortality in other chronic diseases,…
Abstract Number: 1805 • 2017 ACR/ARHP Annual Meeting
Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis
Jessica A. Walsh¹, Christine Willinger², M. Elaine Husni³, Soumya M. Reddy⁴, Jose U. Scher⁵ and Alexis Ogdie⁶, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Pennsylvania, Philadelphia, PA, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data (RAPID3) was developed and validated for rheumatoid arthritis (RA). Little data exist on the use of RAPID3…
Abstract Number: 1806 • 2017 ACR/ARHP Annual Meeting
Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Maria Dall'Era², Laura Trupin³, Stephanie Rush⁴, Charles G. Helmick⁵, Lindsey A. Criswell⁴ and Jinoos Yazdany³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].